Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

计划入组 270 人 · 首次发布于 2016 年 5 月 25 日

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

计划入组 122 人 · 首次发布于 2015 年 5 月 7 日

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

计划入组 220 人 · 首次发布于 2017 年 8 月 4 日

anti-HERV-K therapy

ENV-294

ENV-0205

KIM IVANA K

United States

K-Group Beta, Inc.

United States

K-PAX Pharmaceuticals, Inc.

United States

GeNeuro's GNK-301 Shows Promise in Precision Medicine Approach for ALS

GeNeuro Wins European Patent for GNK-301, an Anti-HERV K Antibody Targeting ALS

Endeavor BioMedicines' ENV-101 Shows Promise in Reversing Idiopathic Pulmonary Fibrosis in Phase II Trials